(R)-2-(1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)-N-(5-(thiazol-2-yl)pyridin-2-yl)propanamide.

35. The compound of claim 34 which is not any one of the following compounds:


2-(1, 3-dimethyl-2,6-dioxo-2,3-dihydro-1H-purin-7(6H)-yl)-N-(4-(pyrimidin-2-yl)phenyl)acetamide,

2-(1,3-dimethyl-2,6-dioxo-2,3-dihydro-1H-purin-7(6H)-yl)-N-(6-(pyridin-4-yl)pyridazin-3-yl)acetamide,

2-(1,3-dimethyl-2,6-dioxo-2,3-dihydro-1H-purin-7(6H)-yl)-N-(5-(4-(2-fluorobenzyl)piperazin-1-yl)pyridin-2-yl)acetamide and

(R)-2-(1,3-dimethyl-2,6-dioxo-2,3-dihydro-1H-purin-7(6H)-yl)-N-(5-(2-methyl thiazol-4-yl)pyridin-2-yl)propanamide.

36. The compound of claim 1 which is:



~~37. The compound of any one of claims 1 to 36 when used for modulation of the Wnt pathway.~~

~~38.~~37. The compound of ~~claim~~ any one of claims 1 to 36 for use in the ~~when used for~~ treatment of a disease or condition associated with Wnt pathway activity.

~~39.~~38. The compound of claim 37~~38~~ wherein the disease or condition is a cancer, such as cervical, colon, breast, bladder, head and neck, gastric, lung, ovarian, prostate, thyroid, non-small-cell lung, as well as chronic lymphocytic leukemia, mesothelioma, melanoma, pancreatic adenocarcinoma, basal cell carcinoma, osteosarcoma, hepatocellular carcinoma, Wilm's tumor or medulloblastoma, or a fibrotic disease, such as pulmonary fibrosis, liver

fibrosis, skin fibrosis or renal fibrosis, or a degenerative disease, or a metabolic disease such as diabetic retinopathy.

~~40. Use of a compound according to any one of claims 1 to 36 for modulating Wnt activity and/or porcupine activity.~~

~~41.~~39. The compound of any one of claims 1 to 36 for use in the modulation of ~~A method of modulating~~ Wnt secretion and/or porcupine activity comprising exposing cells to the~~a~~ compound as described above ~~according to any one of claims 1 to 36~~.

~~42. Use of a compound according to any one of claims 1 to 36 for treatment of a disease or condition associated with Wnt pathway activity.~~

~~43. A method of treating a disease or condition associated with Wnt pathway activity comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to any one of claims 1 to 36.~~

~~44. The use of claim 42 or the method of claim 43 wherein the disease or condition is selected from the group consisting of cancer, fibrosis, stem cell and diabetic retinopathy, rheumatoid arthritis, psoriasis and myocardial infarction.~~

~~45. The use or method of claim 44 wherein the cancer is a cancer characterised by high Wnt activity.~~

~~46.~~40. Use of a compound according to any one of claims 1 to 36 in the manufacture of a medicament for the treatment of a disease or condition associated with Wnt pathway activity.

~~47.~~41. The use of claim ~~40~~46 wherein the disease or condition is selected from the group consisting of cancer, such as cervical, colon, breast, bladder, head and neck, gastric, lung, ovarian, prostate, thyroid, non-small-cell lung, as well as chronic lymphocytic leukemia, mesothelioma, melanoma, pancreatic adenocarcinoma, basal cell carcinoma, osteosarcoma, hepatocellular carcinoma, Wilm's tumor or medulloblastoma, or a fibrotic disease, such as pulmonary fibrosis, liver fibrosis, skin fibrosis or renal fibrosis, or a degenerative disease, or a metabolic disease such as diabetic retinopathy.

~~48.~~42. The use of claim ~~41~~47 wherein the disease or condition is selected from the group consisting of cancer, fibrosis, stem cell and diabetic retinopathy, rheumatoid arthritis, psoriasis and myocardial infarction.

~~49.~~43. The use of claim ~~41~~47 or claim ~~42~~48 wherein the cancer is characterised by high Wnt activity or a fibrotic disease or a degenerative disease.

~~50.~~44. Use of a compound according to any one of claims 1 to 36 in diagnosis.

~~51.~~45. A pharmaceutical composition comprising a compound according to any one of claims 1 to 36 together with one or more pharmaceutically acceptable carriers, diluents or adjuvants.

~~52.~~46. An anhydrous form of the free base of 2-(1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)-N-(6-phenylpyridazin-3-yl)acetamide.

~~53.~~47. The anhydrous form of claim ~~46~~52 which is a non-hydrated single polymorph.

~~54.~~48. The anhydrous form of claim ~~46~~52 or claim ~~47~~53 which is crystalline.

~~55.~~49. The anhydrous form of claim ~~48~~54 which shows on X-ray diffraction a peak on the 2theta scale at 22.2°±0.5°.

~~56.~~50. The anhydrous form of claim ~~48~~54 or claim ~~49~~55 which shows on X-ray diffraction peaks on the 2theta scale at 5.5°±0.5° and 14.2°±0.5°.

~~57.~~51. The anhydrous form of any one of claims ~~48~~54 to ~~50~~56 which shows on X-ray diffraction at least four peaks on the 2theta scale selected from the group consisting of 5.5°±0.5° and 12.5°±0.5°, 14.2°±0.5°, 16.7°±0.5°, 17.7°±0.5°, 18.8°±0.5°, 22.4°±0.5°, 24.2°±0.5° and 31.7°±0.5°.

~~58.~~52. The anhydrous form of any one of claims ~~48~~54 to ~~51~~57 which shows on X-ray diffraction peaks on the 2theta scale of and 5.5°±0.5° and 12.5°±0.5°, 14.2°±0.5°, 16.7°±0.5°, 17.7°±0.5°, 18.0°±0.5°, 18.8°±0.5°, 19.6°±0.5°, 20.6°±0.5°, 22.4°±0.5°, 24.2°±0.5°, 24.4°±0.5°, 25.0°±0.5°, 27.0°±0.5°, 27.6°±0.5°, 29.8°±0.5°, 31.7°±0.5° and 32.2°±0.5°.

~~59.~~53. A pharmaceutical composition comprising an anhydrous free base according to any one of claims 4~~6~~52 to 52~~58~~.

~~60. A method of treating or preventing a proliferative disorder comprising administering a therapeutically effective amount of an anhydrous free base according to any one of claims 52 to 58 to a subject in need thereof.~~

~~61. The method of claim 60 wherein the disorder is a cancer.~~

~~62. Use of an anhydrous free base according to any one of claims 52 to 58 in the treatment of a proliferative disorder.~~

~~63. Use according to claim 62 wherein the proliferative disorder is cancer.~~

~~64.~~54. Use of an anhydrous free base according to any one of claims 4~~6~~52 to 52~~58~~ in the manufacture of a medicament for the treatment of a proliferative disorder.

~~65.~~55. Use according to claim 54~~64~~ wherein the proliferative disorder is cancer.